Shingrix is a onetime vaccination, given in two doses a few months apart. The CDC recommends it starting at age 50 for most ...

Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia ...

Getting vaccinated against shingles may not only lower risk for the condition — it may offer some protection against dementia ...

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

While anyone who has had chicken pox still has the virus in their system, flare-ups in older adulthood are typically more ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

New research has linked the shingles vaccine to a reduced risk of dementia, but who is eligible for the jab and what are the ...

Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

Shingles are more common than people think but there is help in the form of a vaccination. SHINGRIX is an FDA-approved vaccine for the prevention of shingles in adults 50 years ...

Shingrix was hit hard in the first quarter as a result of the prioritisation of COVID-19 vaccination programmes in the US and other markets, with sales dropping almost 50% to £327 million, but ...

Shingrix grew 19% to £833 million in the quarter, backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million, respectively.